cambridge.org/cty

Original Article

Cite this article: Loomba RS, Ikeda N, Farias JS, Villarreal EG, and Flores S (2024). Comorbidities, pharmacologic interventions, and mechanical interventions associated with mortality in isolated diastolic left heart failure: lessons from a national database. *Cardiology in the Young*, page 1 of 7. doi: 10.1017/ S1047951124026787

Received: 11 April 2023 Revised: 18 May 2024 Accepted: 19 September 2024

Keywords:

Diastolic heart failure; CHD; paediatric ICU; cardiovascular drugs

Corresponding author: Juan S. Farias; Email: jsfariast@gmail.com

Comorbidities, pharmacologic interventions, and mechanical interventions associated with mortality in isolated diastolic left heart failure: lessons from a national database

Rohit S. Loomba^{1,2}, Nobuyuki Ikeda¹, Juan S Farias³, Enrique G. Villarreal⁴ and Saul Flores^{5,6}

¹Division of Cardiology, Advocate Children's Hospital, Oak Lawn, IL, USA; ²Department of Pediatrics, Chicago Medical School/Rosalind Franklin University of Medicine and Science, Chicago, IL, USA; ³Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA; ⁴Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico; ⁵Section of Critical Care Medicine and Cardiology, Texas Children's Hospital, Houston, TX, USA and ⁶Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

Abstract

Background: Diastolic heart failure may be noted in paediatric patients with CHD, cardiomyopathy, or malignancies requiring chemotherapy, but the available data are scarce, and often derived from adult trials or based on theoretic or anecdotal evidence. Methods: Data between 2016 and 2021 were obtained from Pediatric Health Information System database. Patients <18 years of age with isolated diastolic heart failure admitted to ICU at some point during admission were included. They were divided into patients with and without inpatient mortality. Patients' demographics, comorbidities using ICD-10 codes, and pharmacologic interventions were also recorded. Univariate analysis was done in demographics, comorbidities, pharmacologic interventions, and mechanical interventions between admissions with and without mortality. Multivariable logistic regression was done for inpatient mortality and multivariable linear regression was done for total hospital length of stay in survivors. Results: Isolated diastolic heart failure comprised 0.5% of critically ill paediatric patients. A total of 121 (5%) experienced mortality among the 2,273 admissions in the final analyses. Milrinone and angiotensin converting enzyme inhibitor were found to be associated with decreased mortality. Increasing age and diuretics were associated with decreased total hospital length of stay in survivors. Conclusion: In the cohort studied, isolated diastolic left heart failure has a 5% mortality. Several comorbidities and interventions are associated with increased mortality with milrinone and angiotensin converting enzyme inhibitors being associated with decreased risk of mortality. When only admissions with survival to discharge are considered, older age and diuretics are associated with lower total hospital length of stay.

Introduction

Diastolic heart failure may be noted in children, specifically those with CHD, cardiomyopathy, and malignancies requiring chemotherapy.¹⁻⁴ There is a paucity of data regarding the management of diastolic heart failure in children. Management of diastolic heart failure in children is often based on data from adult trials or based on theoretic or anecdotal evidence. Unfortunately, paediatric and adult heart failure differ in their aetiology, molecular manifestations, and response to specific treatments.^{3,5} Much of the published work regarding diastolic heart failure in children focuses on etiologic associations and various diagnostic associations.^{3,4}

The primary aim of this study was to use data from a national paediatric inpatient database to determine comorbidities, mechanical interventions, and pharmacologic interventions associated with mortality in critically ill children with isolated diastolic left heart failure.

Methods

As this study utilised deidentified data from a national database, no consents were obtained by the authors of this study. This study is in concordance with the Helsinki Declaration.

Pediatric Health Information System database

Data for this study were obtained from the Pediatric Health Information System (database. Pediatric Health Information System is an administrative and billing database that contains inpatient, emergency department, ambulatory surgery, and observation data from not-for-profit,

 $\ensuremath{\mathbb{C}}$ The Author(s), 2024. Published by Cambridge University Press.



tertiary-care paediatric hospitals in the United States. The 49 hospitals that contribute data to Pediatric Health Information System are affiliated with the Children's Hospital Association (Lenexa, KS), a business alliance of children's hospitals. Data quality and reliability are assured through a joint effort between the Children's Hospital Association and participating hospitals. For the purposes of external benchmarking, participating hospitals provide discharge/encounter data including demographics, diagnoses, procedures, and charges. Data are de-identified at the time of data submission, and data are subjected to a number of reliability and validity checks before being included in the database.

Admission identification

Pediatric Health Information System database data from 2016 to 2021 were utilised for this study. Only data from those who were admitted to the neonatal ICU, pediatric ICU, or pediatric cardiac ICU at some point during the admission were extracted.

First, paediatric patients under 18 years of age were identified. Next, these paediatric admissions were then filtered on whether or not diastolic left heart failure was present. Admissions with diastolic left heart failure with systolic left heart failure or right ventricular failure were then excluded. This was done to result in only paediatric admissions with isolated diastolic left heart failure. "Isolated" is used to refer only to cardiac function, admissions with other cardiac or non-cardiac comorbidities were not excluded.

Paediatric admissions pertaining to isolated diastolic left heart failure were then divided into two groups: those with inpatient mortality and those without.

Admission characteristics

Several data points were captured for each of the included admissions. Age of admission, gender, and year of admission were captured for all admissions. Total hospital length of stay and inpatient mortality were also recorded for all admissions. Any use of "mortality" from here on after will refer to inpatient mortality during the admission of interest.

The presence of comorbidities was captured using ICD-10 codes or database flags. Database flags were utilised for infection, malignancy, need for mechanical ventilation, and need for extracorporeal membrane oxygenation. CHD was captured using ICD-10 codes for the individual lesions and then developing a composite. ICD-10 codes were also utilised to capture the following comorbidities: acute kidney injury, acute hepatic failure, cardiomyopathy, obesity, asthma, pulmonary hypertension, arrhythmia, fluid overload, acidosis, alkalosis, respiratory failure, cardiogenic shock, and cardiac arrest.

Pharmacologic interventions captured included epinephrine, norepinephrine, dobutamine, dopamine, milrinone, vasopressin, enalapril, captopril, lisinopril, labetalol, metoprolol, carvedilol, propranolol, atenolol, esmolol, losartan, sacubitril/valsartan, furosemide, chlorothiazide, acetazolamide, bumetanide, spironolactone, metolazone, torsemide, digoxin, vitamin D, cholecalciferol, carnitine, iron, thiamine, calcium chloride, calcium gluconate, sodium bicarbonate, macitentan, sildenafil, bosentan, inhaled nitric oxide, hydrocortisone, methylprednisolone, dexamethasone, and prednisolone, levothyroxine, liothyronine. Labetalol, metoprolol, carvedilol, propranolol, atenolol, and esmolol were categorised as beta-blockers. Enalapril, captopril, and lisinopril were categorised as angiotensin converting enzyme inhibitors. Sacubitril/valsartan was the only angiotensin receptor blocker and neprolysin inhibitor and was categorised as such. Furosemide, chlorothiazide, acetazolamide, bumetanide, spironolactone, metolazone, and torsemide were categorised as diuretics. Levothyroxine and liothyronine were categorised as thyroid hormone replacement.

Statistical analyses

Continuous variables were described as median and range while categorical variables were described as absolute frequency and percentage. Analyses of continuous variables across groups were conducted using a Mann–Whitney U test while analyses of categorical variables were conducted using a Fisher exact test. Characteristics were compared between paediatric diastolic left heart failure admissions with and without mortality.

Next, regression analyses were conducted to model mortality and then total hospital length of stay in only those who survived. A logistic stepwise regression was conducted to model mortality with mortality as the dependent variable and the collected comorbidities, mechanical interventions, and pharmacologic interventions as independent variables. A *p*-value of 0.10 was used for entry into the model and a *p*-value of 0.05 was used for exclusion.

Next, a linear regression was conducted to model total hospital of length of stay in admissions with survival to discharge with total hospital length of stay in days as the dependent variable and the collected comorbidities, mechanical interventions, and pharma-cologic interventions as independent variables. This was done as a stepwise regression as well with a *p*-value of 0.10 used for entry and a *p*-value of 0.05 used for exclusion.

Statistical analyses were conducted using SPSS Version 23.0. A *p*-value of less than 0.05 was considered statistically significant. Any use of the word "significant", "significantly", or "significance" here after will refer to statistical significance unless explicitly stated otherwise.

Results

Cohort information

A total of 2,394 admissions with isolated diastolic left heart failure were included in the final analyses. As the source dataset included 426,029 admissions total, this represents a 0.5% incidence of isolated diastolic left heart failure among critically ill paediatric patients. Among the 2,273 admissions included in the final analyses, 121 (5%) experienced mortality, and 460 (20%) were single ventricle.

Mortality, univariate analysis

Tables 1 and 2 demonstrate differences in demographics, comorbidities, pharmacologic interventions, and mechanical interventions between admissions with and without mortality.

Mortality, regression analyses

Table 3 demonstrates significant results of the multivariable logistic regression modelling for inpatient mortality. Independent variables entered into the regression that did not yield a significant result are not included in the table. The following factors were found to be associated with decreased mortality: milrinone and angiotensin converting enzyme inhibitors. Milrinone was associated with a 70% reduction in the odds of mortality while angiotensin converting enzyme inhibitors were associated with a 60% reduction in the odds of mortality (Figure 1). The following

Table 1. Comparison of	characteristics and	l comorbidities	between	those wi	th
and without mortality					

	No mortality (<i>n</i> = 2273)	Mortality $(n = 121)$	<i>p</i> -value
Age (months)	29	15	0.04
Male	1,139 (50.1)	64 (52.9)	0.62
CHD	1,666 (73.3)	72 (59.5)	<0.01
Cardiomyopathy	143 (6.3)	14 (11.6)	0.02
Obesity	153 (6.7)	9 (7.4)	0.76
Asthma	191 (8.4)	7 (5.8)	0.30
Pulmonary hypertension	249 (11.0)	23 (19.0)	<0.01
Infection	1,032 (45.4)	94 (77.7)	<0.01
Malignancy	43 (1.9)	12 (9.9)	<0.01
Acute kidney injury	408 (17.9)	75 (62.0)	<0.01
Acute hepatic failure	18 (0.8)	8 (6.6)	<0.01
Arrhythmia	456 (20.1)	50 (41.3)	<0.01
Fluid overload	135 (5.9)	8 (6.6)	0.76
Acidosis	287 (12.6)	49 (40.5)	<0.01
Alkalosis	104 (4.6)	14 (11.6)	<0.01
Respiratory failure	979 (43.1)	91 (75.2)	<0.01
Cardiogenic shock	63 (2.8)	12 (9.9)	<0.01
Cardiac arrest	52 (2.3)	30 (24.8)	<0.01
Need for mechanical ventilation	1,343 (59.1)	110 (90.9)	<0.01
Need for extracorporeal membrane oxygenation	56 (2.5)	35 (28.9)	<0.01
Total hospital length of stay	9 (1 to 550)	35 (1 to 803)	<0.01

factors were found to be associated with increased mortality: acute kidney injury, malignancy, cardiac arrest, need for mechanical ventilation, need for extracorporeal membrane oxygenation, epinephrine, norepinephrine, dopamine, vasopressin, pulmonary vasodilators, carnitine, thiamine, and sodium bicarbonate.

Total hospital length of stay in survivors, regression analysis

Table 4 demonstrates significant results of the multivariable linear regression modelling for total hospital length of stay in survivors. Independent variables entered into the regression that did not yield a significant result are not included in the table. The following factors were found to be associated with decreased total hospital length of stay in survivors: increasing age and diuretics.

Table 5 summarises the general effects of interventions on mortality and length of stay.

Discussion

The findings of this study utilising data from a national inpatient database demonstrate that isolated diastolic dysfunction is present in 0.5% of paediatric admissions in the neonatal ICU, paediatric ICU, or paediatric cardiac ICU. Inpatient mortality is approximately 5% in such admissions. Several comorbidities are associated with increased inpatient mortality. Several pharmacologic interventions are also associated with increased risk of

Table 2. Pharmacologic interventions in paediatric admissions with isolated diastolic left heart failure with and without inpatient mortality

	No mortality $(n = 2273)$	Mortality $(n = 121)$	<i>p</i> -value
Epinephrine	1,337 (58.8)	101 (83.4)	<0.01
Norepinephrine	161 (7.1)	48 (39.7)	<0.01
Dobutamine	23 (1.0)	9 (7.4)	<0.01
Dopamine	584 (25.7)	52 (43.0)	<0.01
Milrinone	1,303 (57.3)	76 (62.8)	0.23
Vasopressin	600 (26.4)	69 (57.0)	<0.01
Beta blocker	661 (29.1)	51 (42.1)	<0.01
Angiotensin converting enzyme inhibitor	755 (33.2)	35 (28.9)	0.32
Angiotensin receptor blocker	38 (1.7)	1 (0.8)	0.47
Angiotensin receptor- neprolysin inhibitor	2 (0.1)	0 (0.0)	0.74
Digoxin	277 (12.2)	21 (17.4)	0.09
Diuretic	2,094 (92.1)	109 (90.1)	0.41
Pulmonary vasodilator	297 (13.1)	38 (31.4)	<0.01
Corticosteroid	1,340 (59.0)	96 (79.3)	<0.01
Thyroid hormone	148 (6.5)	13 (10.7)	0.07
Ascorbic acid	84 (3.7)	16 (13.2)	<0.01
Vitamin D	19 (0.8)	0 (0.0)	0.31
Cholecalciferol	335 (14.7)	30 (24.8)	<0.01
Carnitine	42 (1.8)	19 (15.7)	<0.01
Iron	177 (7.8)	17 (14.0)	0.01
Calcium chloride	1,335 (58.7)	77 (63.6)	0.28
Calcium gluconate	491 (21.6)	63 (52.1)	<0.01
Sodium bicarbonate	1,332 (58.6)	102 (84.3)	<0.01

inpatient mortality although milrinone and angiotensin converting enzyme inhibitors are associated with decreased risk of inpatient mortality. When only admissions with survival to discharge were considered, several factors were associated with increased length of stay while only older age and diuretics were associated with decreased length of stay in survivors.

There are very limited data regarding paediatric diastolic heart failure in general. Much of the data that exist are focused on echocardiographic evaluation of diastolic heart failure.^{6,7} Medical management of isolated paediatric diastolic left heart failure is largely anecdotal, based on theory as well as adult data. The issue with this approach is that theory does not always translate into reality. Furthermore, children and adults have physiologic differences which may lead to different effects of interventions.⁵

What is currently present in the adult literature regarding diastolic heart failure, commonly referred to as heart failure with preserved ejection fraction consists of few large trials. The J-DHF and SENIORS trials demonstrated no benefit of angiotensin converting enzyme inhibitors with all-cause mortality.^{8,9} With respect to angiotensin receptor blockers, the CHARM-preserved and I-PRESERVED trials have demonstrated that these agents are not associated with decreased hospitalisation or mortality in those

Table 3. Logistic regression analysis results modelling mortality in those with isolated diastolic left heart failure

	Beta- coefficient	Odds ratio (95% confidence interval)	<i>p</i> -value
Cardiac arrest	1.6	5.3 (2.7 to 10.4)	<0.01
Acute kidney injury	0.9	2.5 (1.4 to 4.4)	<0.01
Malignancy	1.4	4.0 (1.5 to 10.5)	<0.01
Need for mechanical ventilation	0.9	2.6 (1.2 to 5.7)	0.01
Need for extracorporeal membrane oxygenation	1.7	5.5 (2.7 to 11.4)	<0.01
Epinephrine	0.8	2.3 (1.3 to 4.1)	<0.01
Norepinephrine	0.7	2.1 (1.1 to 3.9)	0.01
Dopamine	0.9	2.5 (1.4 to 4.4)	<0.01
Milrinone	-1.1	0.3 (0.1 to 0.6)	<0.01
Vasopressin	0.8	2.2 (1.2 to 3.9)	<0.01
Angiotensin converting enzyme inhibitor	-0.7	0.4 (0.2 to 0.8)	<0.01
Pulmonary vasodilator	0.9	2.5 (1.4 to 4.4)	<0.01
Carnitine	1.0	2.9 (1.2 to 6.8)	0.01
Thiamine	1.5	4.8 (1.5 to 14.2)	<0.01
Sodium bicarbonate	1.1	3.1 (1.5 to 6.6)	<0.01




Figure 1. Forest plot showing odds ratio of all-cause mortality with pharmacologic interventions.

with heart failure with preserved ejection fraction.¹⁰ The PARAGON heart failure trial did not find benefit of a combined angiotensin receptor and neprolysin receptor blocker in the entire study cohort with respect to heart failure hospitalisation or cardiovascular mortality.¹¹ The TOPCAT trial found no benefit of spironolactone on a composite outcome of heart failure hospitalisation, cardiac arrest, or cardiovascular death.¹² The SENIORS

Table 4. Linear regression analysis results modelling total hospital length of stay in those with isolated diastolic left heart failure

	Beta- coefficient	<i>p</i> -value
Admit age (years)	-0.7	<0.01
Cardiac arrest	15.0	<0.01
Acute kidney injury	7.6	0.01
Acidosis	9.6	<0.01
Alkalosis	18.7	<0.01
Infection	14.1	<0.01
Need for mechanical ventilation	6.2	0.02
Need for extracorporeal membrane oxygenation	16.4	<0.01
Epinephrine	9.2	<0.01
Norepinephrine	8.8	0.01
Angiotensin converting enzyme inhibitor	6.5	<0.01
Digoxin	10.5	<0.01
Pulmonary vasodilator	11.7	<0.01
Steroid	5.5	0.02
Thyroid hormone	15.0	<0.01
Diuretic	-50	<0.01
Vitamin D	29.1	0.02
Ascorbic acid	15.3	<0.01
Carnitine	46.5	<0.01
Iron	43.0	<0.01
Calcium gluconate	16.6	<0.01

and J-DHF trials did not find benefit of beta-blockers with respect to heart failure hospitalisation, cardiovascular death, or all-cause mortality although significant was noted in a subset of patients with higher dose carvedilol.^{8,9} The trials DILATE-1, SOCRATES-PRESERVED, and RELAX did not find benefit of pulmonary vasodilators in mean pulmonary artery pressure, left atrial volume, n-terminal pro-beta-natriuretic peptide levels, or exercise capacity.^{13–15} As previously stated, due to difference in children and adults all the way down to the cellular level, this adult data should not directly be applied to the management of children although it may offer a starting point to help design paediatric trials.

No data on treatment of isolated paediatric diastolic left heart failure truly exist. This is for both the inpatient and outpatient settings. A previous study looked at the impact of inpatient vasoactive medications in those with heart failure after cardiac surgery and found that epinephrine, norepinephrine, dopamine, dobutamine, and vasopressin were associated with increased inpatient mortality. Only milrinone was associated with decreased inpatient mortality.¹⁶

The current study presents the most robust data regarding inpatient paediatric admissions with isolated diastolic heart failure. This study is able to characterise the cohort in general but also identifies factors associated with inpatient mortality. Such data may be helpful in risk-stratifying patients, particularly those at high risk for mortality. The current study also characterises the effect of pharmacologic interventions on inpatient mortality as well as length of stay in those who survive to discharge. **Table 5.** Summary of regression findings on inpatient mortality and total hospital length of stay in survivors only

	Mortality	Total hospital length of stay in survivors
Admit age (years)		Decreased
Cardiac arrest	Increased	Increased
Acute kidney injury	Increased	Increased
Malignancy	Increased	
Infection		Increased
Acidosis		Increased
Alkalosis		Increased
Need for mechanical ventilation	Increased	Increased
Need for extracorporeal membrane oxygenation	Increased	Increased
Epinephrine	Increased	Increased
Norepinephrine	Increased	Increased
Dopamine	Increased	
Milrinone	Decreased	
Vasopressin	Increased	
Digoxin		Increased
Angiotensin converting enzyme inhibitor	Decreased	Increased
Pulmonary vasodilator	Increased	Increased
Steroid		Increased
Diuretic		Decreased
Thyroid hormone		Increased
Vitamin D		Increased
Ascorbic acid		Increased
Carnitine	Increased	Increased
Thiamine	Increased	
Iron		Increased
Calcium gluconate		Increased
Sodium bicarbonate	Increased	

The current study demonstrates that acute kidney injury, malignancy, and cardiac arrest are associated with increased mortality in those with diastolic left heart failure. Malignancy is likely to be a contributing factor to the development of diastolic left heart failure while acute kidney injury and cardiac arrest are likely to be, at least in part, due to the diastolic heart failure. Previous studies have demonstrated that chemotherapy agents utilised for the treatment of malignancy, specifically anthracycline medications, are associated with the development of both diastolic and systolic left heart failure. Acute kidney injury and cardiac arrest, however, are likely a result of impaired oxygen delivery as a result of diastolic left heart failure. It has been well demonstrated that impaired oxygen delivery, as can be clinically monitored by venous saturations, or near-infrared spectroscopy, is associated with increased risk for acute kidney injury and cardiac arrest.

In regard to mechanical interventions, the need for mechanical ventilation and extracorporeal membrane oxygenation is noted to be associated with increased mortality in diastolic left heart failure. These likely represent a cohort of patients with greater severity of illness which may be due to the diastolic left heart failure itself or other comorbidities. The association of need for mechanical ventilation and need for extracorporeal membrane oxygenation with increased mortality is previously described.

With regards to vasoactive medications, epinephrine, norepinephrine, dopamine, and vasopressin were all associated with increased mortality while milrinone was the only agent that was associated with decreased mortality. No significant association of dobutamine with mortality is noted by the current study. The association of most vasoactive medications with increased mortality, even after adjusting for comorbidities and other pharmacologic interventions, likely represents some underlying effect of the vasoactive medications themselves but also likely is also modulated by severity of illness as sicker patients are more likely to require vasoactive medications. This is not the first study to have noted that vasoactive medications may be associated with increased inpatient mortality. This has been demonstrated in both paediatric and adult patients, in those with and without heart failure.^{16,25}

Systemic oxygen delivery is the product of oxygen content and cardiac output. Oxygen content can further be broken down into the components of arterial saturation and haemoglobin while cardiac output can further be broken down into the components of preload, afterload, and contractility. Many vasoactive agents increase myocardial oxygen consumption which may come at the expense of systemic oxygen delivery. Many vasoactive agents also have an arterial constrictor effect. Increasing left ventricular afterload may further impact stroke volume and systemic oxygen delivery. It is important to note that simply augmenting mean arterial blood pressure does not imply augmentation of stroke volume and that increased mean arterial blood pressure may be associated with decreased stroke volume if systemic vascular resistance increases a substantial amount. Milrinone can decrease afterload and improve contractility, both of which can help augment cardiac output. Furthermore, milrinone's leusotropic properties can help improve ventricular filling, which in the setting of diastolic left heart failure may be of obvious benefit. This may explain the beneficial effect milrinone on survival noted in this study. Previous studies have also demonstrated the beneficial effects of milrinone on systemic oxygen delivery and outcomes, specifically in prevention of low cardiac output syndrome after cardiac surgery.²⁶

With regards to enteral medications, digoxin and beta-blockers are noted to have a significant association with mortality. Angiotensin converting enzyme inhibitors are noted to be associated with decreased mortality. This may be due to the afterload reduction effects of these agents.

Pulmonary vasodilators are noted to be associated with increased mortality in the current study. This differs from adult studies which demonstrate no change.

With respect to length of stay in survivors, older age and diuretics tended to be associated with decreased length of stay. The association of younger age with increased mortality in paediatric heart failure has been previously described. The association of diuretics with decreased length of stay is likely secondary to symptomatic management and underlying decrease in left ventricular filling pressures associated with diuretics.

While these data are additive to the current literature, specifically for a physiology for which much data do not exist, these data are not without their limitations. First, the definition of paediatric diastolic heart failure is not clearly defined, so its diagnosis and timing likely have physician and institutional variability. Second, the timing of onset of diastolic left heart failure and the comorbidities is not available. Thus, temporal associations cannot be characterised objectively. The temporal associations are discussed elsewhere in this manuscript in the setting of previously published data. Third, the dose and duration of mechanical and pharmacologic interventions cannot be characterised. Thus, dosedependent effects of medications are not able to be characterised. Fourth, comorbidities are captured by coding. How specific comorbidities are defined may differ at the physician and institution levels. Thus, what one individual or institution defines as acute kidney injury or liver failure, for instance, may be different. Fifth, laboratory data such as N-terminal-pro-brain-natriuretic peptide and serum creatinine are not available in the database. Sixth, imaging data are also not available in the database. Specifically, with respect to the specific aims of this study, echocardiographic data such as tissue Doppler around the mitral valve, mitral valve inflow Doppler, or pulmonary venous Doppler data to characterise left heart diastolic function are not available. Seventh, as with any data that are sourced from multiple centres, individual and institutionallevel variability is present. Eight, the overall frequency of use of the combined angiotensin receptor blocker and neprolysin inhibitor combination was too low to allow for regression analysis. Finally, these findings are representative of the average in this cohort, conclusions cannot be drawn for outlying subsets.

To overcome the issue of severity of illness which is exacerbated by the lack of laboratory, haemodynamic, and imaging data this study used various comorbidities that are associated with severity of illness. Examples of this include acute kidney injury, liver failure, and respiratory failure. It is well demonstrated that the number of impacted organ systems correlates well with severity of illness and mortality in critically ill children. Medications also serve as a surrogate marker, specifically vasoactive medications. The vasoinotrope score is based on this very principle and is demonstrated to correlate with severity of illness and mortality. Being able to include a large number of comorbidities and pharmacologic agents in the regression analyses allows for an indirect adjustment for severity of illness. To overcome the issue of institutional variability in clinical practice, centre was entered as an independent variable into the regression analyses to adjust for some of the institutional-level variability.

It must also be noted that the data are specific to outcomes of inpatient admissions. Chronic effects, outpatient symptom effects, and readmission effects cannot be assessed by these data.

On the most general level with regard to any inpatient admission the most general goal is survival. More specific goals for inpatient admissions then become minimising morbidity to maximise quality of life, minimising length of stay for survivors, and optimising systemic and regional oxygen delivery. The nature of the database allowed for modelling survival and length of stay. More granular analyses were not possible from this database. Nonetheless, these data offer objective insight into inpatient management of this unique patient population. These data can be used to help guide acute clinical management in an ICU setting but, more importantly, can be used as pilot data to help with design of future studies.

Conclusion

In the cohort studied, isolated diastolic left heart failure has a 5% mortality. Several comorbidities and interventions are associated with increased mortality with milrinone and angiotensin converting

enzyme inhibitors being associated with decreased risk of mortality. When only admissions with survival to discharge are considered, older age and diuretics are associated with lower total hospital length of stay.

Availability of data and material. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgements. None.

Financial support. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interests. The authors have no relevant financial or non-financial interests to disclose.

Ethical standard. These analyses did not require institutional review board approval as they used previously published data that were deidentified. These analyses are in compliance with the Helsinki Declaration of 1975 and its subsequent revisions.

References

- Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J 1995; 73:340–350. DOI: 10.1136/hrt.73.4.340.
- Iarussi D, Galderisi M, Ratti G et al. Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. Clin Cardiol 2001; 24: 663–669. DOI: 10.1002/clc.4960241006.
- Pan B, Hu D, Sun H, Lv T, Xu W, Tian J. Pediatric diastolic heart failure: clinical features description of 421 Cases. Front Pediatr 2022; 10: 846408. DOI: 10.3389/fped.2022.846408.
- Butnariu A, Zamfir C, Iancu M, Iacob D, Samasca G, Lupan I. Systolic and diastolic function in congestive heart failure pediatric patients. Rom J Intern Med 2016; 54: 37–46. DOI: 10.1515/rjim-2016-0004.
- Das BB. Therapeutic approaches in heart failure with preserved ejection fraction (HFpEF) in children: present and future. Paediatr Drugs 2022; 24: 235–246. DOI: 10.1007/s40272-022-00508-z.
- Recher M, Botte A, Soquet J, Baudelet JB, Godart F, Leteurtre S. Assessment of left-ventricular diastolic function in pediatric intensive-care patients: a review of parameters and indications compared with those for adults. World J Pediatr 2021; 17: 21–30. DOI: 10.1007/s12519-020-00369-x.
- Dragulescu A, Mertens L, Friedberg MK. Interpretation of left ventricular diastolic dysfunction in children with cardiomyopathy by echocardiography: problems and limitations. Circ Cardiovasc Imaging 2013; 6: 254–261. DOI: 10.1161/CIRCIMAGING.112.000175.
- Yamamoto K, Origasa H, Hori M, Investigators JD. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese diastolic heart failure study (J-DHF). Eur J Heart Fail 2013; 15: 110–118. DOI: 10.1093/eu rjhf/hfs141.
- Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–225. DOI: 10.1093/eurheartj/ehi115.
- Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003; 362 : 777–781. DOI: 10.1016/ S0140-6736(03)14285-7.
- Solomon SD, McMurray JJV, IS Anand et al.angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381: 1609–1620. DOI: 10.1056/NEJMoa1908655.
- Pitt B, Pfeffer MA, Assmann SF et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 10: 1383–1392. DOI: 10.1056/NEJMoa1313731.
- Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind,

placebo-controlled, single-dose study. Chest 2014; 146: 1274–1285. DOI: 10. 1378/chest.14-0106.

- 14. Pieske B, Maggioni AP, Lam CSP et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017; 38: 1119–1127. DOI: 10.1093/eurheartj/ehw593.
- 15. Hussain I, Mohammed SF, Forfia PR et al. Impaired right ventricularpulmonary arterial coupling and effect of sildenafil in heart failure With preserved ejection fraction: an ancillary analysis from the phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial. Circ Heart Fail 2016; 9: e002729. DOI: 10.1161/ CIRCHEARTFAILURE.115.002729.
- Loomba RS, Flores S. Use of vasoactive agents in postoperative pediatric cardiac patients: insights from a national database. Congenit Heart Dis 2019; 14: 1176–1184. DOI: 10.1111/chd.12837.
- Loomba RS, Rausa J, Sheikholeslami D et al. Correlation of near-infrared spectroscopy oximetry and corresponding venous oxygen saturations in children with congenital heart disease. Pediatr Cardiol 2022; 43: 197–206. DOI: 10.1007/s00246-021-02718-7.
- Law MA, Benscoter AL, Borasino S et al. Inferior and superior vena cava saturation monitoring after neonatal cardiac surgery. Pediatr Crit Care Med 2022; 23: e347–e355. DOI: 10.1097/PCC.00000000002963.
- Tweddell JS, Ghanayem NS, Mussatto KA et al. Mixed venous oxygen saturation monitoring after stage 1 palliation for hypoplastic left heart syndrome. Ann Thorac Surg 2007; 84: 1301–1311. DOI:10.1016/j.athoracsu r.2007.05.047.

- Ghanayem NS, Hoffman GM. Near infrared spectroscopy as a hemodynamic monitor in critical illness. Pediatr Crit Care Med 2016; 17: S201–S206. DOI: 10.1097/pcc.00000000000780.
- Hoffman GM, Ghanayem NS, Scott JP, Tweddell JS, Mitchell ME, Mussatto KA. Postoperative cerebral and somatic near-infrared spectroscopy saturations and outcome in hypoplastic left heart syndrome. Ann Thorac Surg 2017; 103: 1527–1535. DOI: 10.1016/j.athoracsur.2016. 09.100.
- Schranz D, Schmitt S, Oelert H et al. Continuous monitoring of mixed venous oxygen saturation in infants after cardiac surgery. Intensive Care Med 1989; 15: 228–232. DOI: 10.1007/BF00271056.
- Rossi AF, Seiden HS, Gross RP, Griepp RB. Oxygen transport in critically ill infants after congenital heart operations. Ann Thorac Surg 1999; 67: 739–744. DOI: 10.1016/s0003-4975(98)01255-7.
- Sheikholeslami D, Dyson AE, Villarreal EG et al. Venous blood gases in pediatric patients: a lost art? Minerva Pediatr (Torino) 2022; 74: 789–794. DOI:10.23736/S2724-5276.21.06464-8.
- 25. Abraham WT, Adams KF, Fonarow GC et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57–64. DOI: 10.1016/j.jacc.2005.03.051.
- Hoffman TM, Wernovsky G, Atz AM et al. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics. Am Heart J 2002; 143: 15–21. DOI: 10.1067/mhj.20021. 20305.